ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia
Under a Creative Commons license
open access
Keywords
5-HT5A receptor antagonist
Schizophrenia
Co-administration
Cognitive impairment
Adverse effect
Cited by (0)
Copyright © 2014 Elsevier B.V. and ECNP.